SEARCH

SEARCH BY CITATION

References

  • 1
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 122131.
  • 2
    Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 1429.
  • 3
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 11039.
  • 4
    Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 6649.
  • 5
    Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 1127.
  • 6
    Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91100.
  • 7
    Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 13440.
  • 8
    Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 15460.
  • 9
    Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 4207.
  • 10
    Hui AY, Wong VW, Chan HL, et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21: 40713.
  • 11
    Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 320.
  • 12
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 120219.
  • 13
    Sanyal AJ, American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 170525.
  • 14
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 246774.
    Direct Link:
  • 15
    Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898906.
  • 16
    Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg 2005; 15: 497501.
  • 17
    Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 144957.
  • 18
    Joseph AE, Saverymuttu SH, Al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43: 2631.
  • 19
    Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 184450.
  • 20
    Borkman M, Storlien LH, Pan DA, Jenkins AB, Chisholm DJ, Campbell LV. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N Engl J Med 1993; 328: 23844.
  • 21
    Storlien LH, Baur LA, Kriketos AD, et al. Dietary fats and insulin action. Diabetologia 1996; 39: 62131.
  • 22
    Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004; 106: 63543.
  • 23
    Benatti P, Peluso G, Nicolai R, Calvani M. Polyunsaturated fatty acids: biochemical, nutritional and epigenetic properties. J Am Coll Nutr 2004; 23: 281302.
  • 24
    Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal β-oxidation, PPARα, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G13339.
  • 25
    Clarke SD. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol 2001; 281: G8659.
  • 26
    Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 128696.
  • 27
    Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 1987; 237: 8858.
  • 28
    Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38: 152939.
  • 29
    Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fisher 344 rats. Hepatology 2004; 39: 60816.
  • 30
    Fidanza F, Gentile MG, Porrini M. A self-administered semiquantitative food-frequency questionnaire with optical reading and its concurrent validation. Eur J Epidemiol 1995; 11: 16370.
  • 31
    World Health Organization. International Guide for Monitoring Alcohol Consumption and Related Harm. Geneva, Switzerland: World Health Organization, Department of Mental Health and Substance Dependence, Noncommunicable Diseases and Mental Health Cluster, 2000.
  • 32
    Taylor KJ, Riely CA, Hammers L, et al. Quantitative US attenuation in normal liver and in patients with diffuse liver disease: importance of fat. Radiology 1986; 160: 6571.
  • 33
    Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Bianchi G, Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis 2004; 36: 40611.
  • 34
    Kakkos SK, Yarmenitis SD, Tsamandas AC, Gogos CA, Kalfarentzos F. Fatty liver in obesity: relation to Doppler perfusion index measurement of the liver. Scand J Gastroenterol 2000; 35: 97680.
  • 35
    Joy D, Scott BB. To perform or not to perform liver biopsy: an alternative view. Gut 2003; 52: 610 [Letter].
  • 36
    Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 74550.
  • 37
    Capanni M, Biagini MR, Centenaro GR, et al. Duplex Doppler ultrasound in the diagnosis of chronic liver disease. Dig Liver Dis 2003; 35 (Suppl. 4): S95 [Abstract].
  • 38
    Fowler RC, Harris KM, Swift SE, Ward M, Greenwood DC. Hepatic Doppler perfusion index: measurement in nine healthy volunteers. Radiology 1998; 209: 86771.
  • 39
    Kasahara A, Hayashi N, Sasaki Y, et al. Hepatic circulation and hepatic oxygen consumption in alcoholic and nonalcoholic fatty liver. Am J Gastroenterol 1988; 83: 8469.
  • 40
    Seifalian AM, Chidambaram V, Rolles K, Davidson BR. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transpl Surg 1998; 4: 717.
  • 41
    Diehl AM. Fatty liver, hypertension, and the metabolic syndrome. Gut 2004; 53: 9234.